Xvivo Perfusion AB (publ) reported earnings results for the fourth quarter and full year ended December 31, 2023. For the fourth quarter, the company reported sales was SEK 155.74 million compared to SEK 131.51 million a year ago. Net income was SEK 68.47 million compared to SEK 0.734 million a year ago. Basic earnings per share from continuing operations was SEK 2.17 compared to SEK 0.02 a year ago. Diluted earnings per share from continuing operations was SEK 2.17 compared to SEK 0.02 a year ago.
For the full year, sales was SEK 597.54 million compared to SEK 415.29 million a year ago. Net income was SEK 91.82 million compared to SEK 18.43 million a year ago. Basic earnings per share from continuing operations was SEK 3.07 compared to SEK 0.62 a year ago. Diluted earnings per share from continuing operations was SEK 3.07 compared to SEK 0.62 a year ago.